Leerink affirms Merck (NYSE: MRK) at Market Perform with a price target of $67 after the company announced topline results ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

Leerink Partners Reiterates Market Perform on Merck (MRK) Following 3Q EPS Beat October 28, 2015 9:31 AM Leerink Partners Remains Bullish After Opdivo and HCV Help Drive 3Q Beat for Bristol-Myers Squibb (BMY)October 28, 2015 8:20 AM EMD Millipore Introduces Parteck® SRP 80 Excipient for Sustained-Release Oral Solid Dose FormulationsOctober 26, 2015 11:50 AM Merck (MRK) Announces KEYTRUDA Met Primary Endpoint in KEYNOTE-010 StudyOctober 26, 2015 9:02 AM Merck’s KEYTRUDA® (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1October 26, 2015 9:01 AM Merck and the National Sleep Foundation Urge Insomnia Sufferers to Prioritize Sleep and Move Beyond TiredOctober 26, 2015 8:01 AM